Company / Accounts Receivable
Upstream Bio, Inc. Accounts Receivable History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$668.0K
FY2025
5-year range
$98.0K / $668.0K
FY2023-FY2025
Trend
+9.0%
vs FY2024
Sector context
#107 of 113
Health Care
What the data says
Among 113 Health Care companies, Upstream Bio, Inc. is in the bottom 5% for accounts receivable. Improved from $98,000 to $668,000 over the past 2 years.
Based on SEC 10-K filings.
$668,000 in FY2025.
Improved from $98,000 to $668,000 over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 5% in Health CareTop 95% of 113This company $668.0K Sector average $1.1B
▼
-99.9% below sector average
Key checks
Key Insights
- In FY2025, accounts receivable increased 9.0% year-over-year.
- Ranks #107 out of 113 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 8.68 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $668.0K | +9.0% |
| FY2024 | $613.0K | +525.5% |
| FY2023 | $98.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026